The Primary CNS Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary CNS Lymphoma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Primary CNS Lymphoma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary CNS Lymphoma and features dormant and discontinued products.

GlobalData tracks 31 drugs in development for Primary CNS Lymphoma by 27 companies/universities/institutes. The top development phase for Primary CNS Lymphoma is phase ii with 20 drugs in that stage. The Primary CNS Lymphoma pipeline has 29 drugs in development by companies and two by universities/ institutes. Some of the companies in the Primary CNS Lymphoma pipeline products market are: Bristol-Myers Squibb, Nurix Therapeutics and Curis.

The key targets in the Primary CNS Lymphoma pipeline products market include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2), Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), and B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).

The key mechanisms of action in the Primary CNS Lymphoma pipeline product include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Inhibitor with eight drugs in Phase II. The Primary CNS Lymphoma pipeline products include 12 routes of administration with the top ROA being Oral and five key molecule types in the Primary CNS Lymphoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Primary CNS Lymphoma overview

Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with Epstein-Barr virus infection. PCNSL usually presents with neurological symptoms such as headache, seizure, cranial nerve deficits, or altered mental status, depending on the location and size of the tumor. The diagnosis of PCNSL requires histopathological confirmation from CSF cytology, vitreous biopsy, or brain/leptomeningeal biopsy. MRI or contrast-enhanced CT typically shows multiple ring-enhancing lesions in the deep white matter. The treatment of PCNSL consists of high-dose methotrexate-based chemotherapy, followed by consolidation with radiation, maintenance therapy, or stem cell transplant. The prognosis of PCNSL is poor, with a 5-year survival rate of 30-40%.

For a complete picture of Primary CNS Lymphoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.